The OsteoCool™ Post-Market Clinical Study (OPuS One) is one of the largest studies in radiofrequency (RF) ablation evaluating outcomes in patients with painful metastatic tumours and benign bone tumours. This multicenter study is collecting real world evidence on the effectiveness and safety of OsteoCool. OPuS One is a global, prospective, non-randomized, single-arm study. Data on the first 100 patients is now available.
Cory’s breast cancer metastasized to her spine and sacrum causing unrelenting lower back pain that brought her into the ER. Not wanting to remain on opioids for her pain, Cory asked her doctor about other options. Dr. Ramsin Benyamin at Millennium Pain Center in Normal, Ilinois (US) offered to treat Cory’s cancer pain with OsteoCool.
The OsteoCool RF ablation system is cooled radiofrequency ablation technology. It offers simultaneous, dual-probe capabilities for treating painful bone tumours, including benign and painful metastatic lesions. The system’s algorithms are designed to perform optimally in bone, allowing you to overcome challenges through a wide range of ablation scenarios, letting you treat patients confidently and consistently.